Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript Summary
Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript Summary
The following is a summary of the Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript:
以下是 Brainstorm Cell Therapeutics Inc. (BCLI) 2024年第二季度業績會交流摘要:
Financial Performance:
金融業績：
Brainstorm reported a net loss of $2.5 million for Q2 2024 compared to a net loss of $5.3 million for Q2 2023, showing an improvement in reducing losses.
Cash reserves increased to $3.65 million as of June 30, 2024, up from $0.75 million on the same date in 2023.
Brainstorm 報告2024年Q2的淨虧損爲250萬元，而Q2 2023年的淨虧損爲530萬元，顯示降低虧損的改進。
現金儲備從2023年同日的75萬元增至2024年6月30日的365萬元。
Business Progress:
業務進展：
Continued preparations for the Phase 3b trial for NurOwn in ALS.
Achieved a written SPA agreement with the FDA, indicating readiness to initiate the trial by the end of 2024 or the first quarter of 2025.
Building a network of 12 leading clinical centers for broad patient access.
Pursuing non-dilutive funding opportunities including a grant application which could bring in up to $15 million.
繼續爲 NurOwn 在ALS的第三期 30億試驗做準備。
與FDA達成編寫SPA協議的共識，表明將在2024年底或2025年初啓動試驗。
打造一個由12個領先臨床中心組成的網絡，以便更廣泛地爲患者提供服務。
追求非稀釋性資金機會，包括申請可以帶來多達1500萬元的撥款。
Opportunities:
機會：
Expanded clinical trial network planned for Phase 3b supports broad patient access and potential for faster enrollment and driving successful trial outcomes.
Exploring non-dilutive funding sources such as grants and strategic partnerships to strengthen financial position.
Potential significant breakthrough in treatment for ALS could position the company positively within the neurodegenerative disease treatment market.
擴大試驗網絡，計劃在第3期30億中提供廣泛的患者接入，從而有助於更快地招募病人並推動試驗結果的成功。
探索非稀釋性資金來源，例如撥款和戰略伙伴關係，以加強財務地位。
ALS治療的可能重大突破，有望在神經退行性疾病治療市場中使公司處於積極地位。
Risks:
風險：
Required to maintain a $1 share price over 10 consecutive trading days to avoid NASDAQ delisting. Exploring a reverse stock split as a remedial action.
需要在連續10個交易日內維持1美元的股價以避免納斯達克除牌。正在探索進行逆向股票拆分。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。